All In Biotech

Drug Trial Radar · NCT07929051

A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig

A Single-arm, Open-label, Safety Rollover Trial of Obrixtamig in Patients With Different Tumours

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Mar 4, 2027

Primary completion

Jul 3, 2028

Study completion Jul 3, 2028

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with advanced cancer who received obrixtamig (BI 764532) in one of several previous studies and benefited from treatment. The goal of this study is to find out how well participants who received obrixtamig in a previous study tolerate obrixtamig. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Participants in this study continue receiving obrixtamig and any other study or standard of care anti-cancer medicines they received in their previous study at the same doses and following the same treatment schedule. Treatments are given in 3-week cycles as infusions into a vein. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit the study site regularly. During the visits, study doctors check participants' health and take note of any unwanted effects.

Conditions

  • Advanced Cancer

Interventions

  • ObrixtamigBiological

    Obrixtamig

  • EzabenlimabBiological

    Ezabenlimab

  • AtezolizumabBiological

    Atezolizumab

  • TopotecanDrug

    Topotecan

  • TocilizumabBiological

    Tocilizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of treatment-emergent adverse events ( AEs) during the on-treatment period.Time frame: Up to 36 months

Locations

15 sites in 6 countries. Site status is shown where the registry gives one.

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • INS Bergonie

    Bordeaux, France

  • Hopital Louis Pradel

    Bron, France

  • INS Curie

    Paris, France

  • HOP Civil

    Strasbourg, France

  • Institut Gustave Roussy

    Villejuif, France

  • Technische Universität Dresden

    Dresden, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany

  • Universitätsklinikum Würzburg AÖR

    Würzburg, Germany

  • Saitama Medical University International Medical Center

    Saitama, Hidaka, Japan

  • National Cancer Center Hospital

    Tokyo, Chuo-ku, Japan

  • Medical University Gdansk

    Gdansk, Poland

  • Polish Mother's Memorial Hospital - Research Institute

    Lodz, Poland

  • Hospital Universitario Ramon Y Cajal

    Madrid, Spain

  • Fundación Jiménez Díaz

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.